Navigation Links
Wiley X Eyewear(R) Announces Successful Resolution of Patent Infringement Litigation Against PanOptx(R), Inc.
Date:10/12/2007

PanOptx Admits Infringement and Agrees to Stop Selling Infringing Products

LIVERMORE, Calif., Oct. 12 /PRNewswire/ -- Wiley X Eyewear(R), the industry leader in the research and development of protective eyewear, won a major court battle against PanOptx(R), Inc. for infringing upon Wiley X's U.S. Patent No. 6,062,688 (the "'688 Patent"). Under the settlement, PanOptx will have to stop selling its Velocity CV and Warrior products to the military by the end of the year, and to all other market segments by the end of 2008. PanOptx will also be required to pay Wiley X royalties on all 2008 sales of these products.

This is a major settlement for Wiley X, whose cutting-edge technology provides critical eye protection for the FBI, DEA, Army Rangers, Navy SEALs and other elite Special Forces Units. "While we would have preferred not to have to litigate, we are very pleased that our patent rights have been vindicated, and that infringing products will be off the market as a result of this settlement," said Dan Freeman, Vice-President of Wiley X Eyewear. "We upheld a principle, and will not hesitate to do so again if our patent rights are not respected in the future."

Wiley X Eyewear began litigation in 2005 to enforce its rights under the '688 Patent, which covers unique aspects of Wiley X's Climate Control Series. PanOptx has acknowledged the validity of the '688 Patent, which protects the unique technology behind the series' removable, air permeable shield that provides eye protection while preventing fogging. This affects sales of PanOptx's Velocity CV series of frames -- including the Raptor CV, Sirocco CV, Diablo CV, Kona CV, Gust CV, Convertible CV, Solano CV, Bora CV, Churada CV, Whirlwind CV and Chubasco CV -- as well as the Warrior product lines -- including the Warrior V-Zero Ballistic and Warrior Tactical models.

With 20 years of innovation in providing advanced eyewear solutions to the military and commercial markets, Wiley X is looki
'/>"/>

SOURCE Wiley X Eyewear
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. Publishers John Wiley & Sons Enter Into An Agreement With NASPGHAN And AASLD
2. PM announces a new health care order for India
3. Ramdoss Announces Introduction of RCH-II
4. Britain Announces Third Transfusion Related Mad Cow Case
5. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
6. Tibet Announces the Dalai Lama’s Tour of South Americ
7. NHS announces further Cost cutting Measures
8. Indian PM Announces Of Setting Up India Study Center At Tashkent
9. PowderMed Announces Needle-Less Flu Vaccine
10. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
11. Australian Government Announces Survey To Tackle Childhood Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Royalty Pharma Announces that Alexander von Perfall Joins Management Team 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7Arctic lake sediments show warming unique ecological changes in recent decades 10450 1Arctic lake sediments show warming unique ecological changes in recent decades 10450 2Arctic lake sediments show warming unique ecological changes in recent decades 10450 30 2 second test for explosive liquids 14554 10 2 second test for explosive liquids 14554 2Smallest nanoantennas for high speed data networks 14552 1Smallest nanoantennas for high speed data networks 14552 2Smallest nanoantennas for high speed data networks 14552 3